Organization | Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Torino Italy (1983)

Organization Overview

First Clinical Trial

2005

NCT00803530

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (20)

allogeneic adipose derived mesenchymal stem cell (1 trial)

bleomycin (blenoxane) (2 trials)

bortezomib (velcade) (2 trials)

carmustine (bicnu) (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

cytarabine (cytosar-u) (2 trials)

dacarbazine (dtic-dome) (2 trials)

doxorubicin (Doxil) (4 trials)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (1 trial)

Filgrastim (neupogen) (2 trials)

mitoxantrone (novantrone) (2 trials)

multivitamins (1 trial)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (5 trials)

sargramostim (leukine) (1 trial)

urea (2 trials)

vinblastine (velban) (2 trials)

vincristine (oncovin) (2 trials)

Drugs in Phase 2 Trials (6)

arsenic trioxide (trisenox) (1 trial)

bendamustine (treanda) (1 trial)

decitabine (dacogen) (1 trial)

ibritumomab tiuxetan (Zevalin) (1 trial)

lenalidomide (revlimid) (2 trials)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hodgkin Disease (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 26